Q-omics provides the consensus-scored C19orf38 profile across patient tissues and cancer cell-line models. C19orf38 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, C19orf38 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, C19orf38 RNA expression shows 17,803 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, KIRC, and LSCC as cancer lineages where C19orf38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C19orf38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C19orf38 survival associations across molecular data types. C19orf38 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C19orf38 RNA expression–survival associations across cancer types. High C19orf38 expression shows unfavorable associations in KIRP, ACC and THYM, but favorable associations in CESC, HNSC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for C19orf38 RNA expression.
This table summarizes C19orf38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C19orf38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C19orf38 shows lower tumor expression in KICH, LUAD, LUSC and UCEC and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher C19orf38 RNA expression in tumor versus normal tissue (log2 FC = +1.252, t-test p < 0.001).
This table shows molecular features associated with C19orf38 in patient tissues and cancer cell lines. In patient samples, C19orf38 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C19orf38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
